Puma Biotechnology to Present Clinical Data on PB272 at American Society of Clinical Oncology 2012 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (OTCBB: PBYI), a development stage biopharmaceutical company, announced that clinical data for its lead drug candidate PB272 (neratinib) in patients with metastatic breast cancer will be presented in the HER2/ER Breast Cancer poster session at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. The ASCO Annual Meeting will be held June 1 – 5, 2012, in Chicago.